Integrative Medicine in Stroke

MARIA JUAREZ-REYES, MD., PH.D.
ASST CLINICAL PROFESSOR, DEPT OF MEDICINE
STANFORD UNIVERSITY
Objectives

- Discuss role of dietary modification in reducing stroke risk
- List 2 components of integrative care for stroke
- Discuss the role of mindfulness on stroke risk factors
- Know resources for investigating primary research in integrative medicine
Outline

- Integrative Medicine
- Evidence of Benefit – Mediterranean Diet
- Emerging Evidence – Gut Microbia
- Controversies – Vit D and CV Risk
- Must Do’s – Mindfulness
- Resources
Integrative Medicine

National Institutes of Health:

Integrative medicine “combines mainstream medical therapies and CAM therapies for which there is some high-quality scientific evidence of safety and effectiveness.”

Dr. Andrew Weil:

“healing orientation” that takes into consideration the whole person (mind, body, spirit) as well as lifestyle
Evidence of Benefit: Mediterranean Diet
Definition of the Mediterranean Diet (MeD): at least two of the following seven components

1. High ratio of monounsaturated to saturated fat
2. Some red wine consumption defined as low to moderate
3. High legume consumption
4. Significant grain and cereal consumption
5. Significant consumption of fruits and vegetables
6. Moderate consumption of milk and dairy products
7. Low consumption of meats and meat products with increased fish

Rees K et al., 2013
MeD: Early Findings of Benefit

- Seven Countries study in 60’s found lower CV mortality rate in Mediterranean countries (Greece, Italy) compared to USA and Finland
- Early prospective studies found reduced CV morbidity & mortality
- More recent prospective cohort studies found dose response relationships -> the greater the adherence to MeD, the greater reduction in:
  - overall mortality
  - CV morbidity and mortality
MeD RTC: PREDIMED TRIAL

- **Eligibility**: 7447 subjects with either DM or 3 major CV RF (tobacco, HTN, elevated LDL, low HDL, obese, Fhx of early CAD)

- **Intervention**: Either MeD supplemental extra virgin olive oil (1 l/week) or MeD supplemental mixed nuts (30 gr/QD). Controls counseled on low fat diet. Dietician ran baseline and quarterly educational sessions.

- **Results**: Reduced **Composite Score** (MI, CVA, death from CV causes)
  - MeD & olive oil – (HR) 0.70 (95% confidence interval), 0.53 - 0.91
  - MeD & nuts – 0.70 (0.53 to 0.94)
  - Overall RR 30%

- Reduced Stroke events in both groups
  - MD with olive oil & nuts respectively, 0.67 (0.46–0.98), 0.54 (0.35–0.84)

Estruch et al., 2006; Martinez-Gonzales et al., 2015
MeD RCT: CV Risk Factors Reduced

- **Cholesterol/HDL**
  - MeD with olive oil and nuts respectively, $-0.32$ ($-0.45$ to $-0.18$), $-0.17$ ($-0.27$ to $-0.02$)

- **LDL – olive oil group**

- **Glucose (mg/dl)**
  - MeD with olive oil and nuts respectively, $-3.8$ ($-7.4$ to $-0.2$), $-2.5$ ($-5.5$ to $0.5$)

- **Systolic BP - (mean change from baseline)**
  - MeD with olive oil and nuts respectively, $-4.8$ mmHg ($-6.7$ to $-2.7$), $-6.5$ mmHg ($-8.7$ to $-4.3$)

- **Diastolic BP**
  - MeD with olive oil and nuts respectively, $-2.5$ mmHg ($-3.5$ to $-1.5$), $-3.6$ mmHg ($-4.7$ to $-2.5$)

- **CRP – olive oil group**

- **IL6 – both MeD diet groups**

Estruch et al., 2006; Martinez-Gonzales et al., 2015
MeD Compliance and Incidence of Stroke

- REGARDS Study - Prospective Cohort Study of 30239 subjects
- “Stroke belt” of US oversampled
- Baseline Food Frequency Questionnaire
  - MeD adherence computed as low, moderate, high
  - Low adherence group was used as “reference” or control
- Telephone interview Q 6 months to eval for CVA
- Followed for 6.5 years

Howard et., 2006; Tsivgoulis et al., 2015
### Association of MeD Adherence Stratified by Tertiles With Incident Ischemic Stroke

<table>
<thead>
<tr>
<th>MeD Adherence Level</th>
<th>Crude Reference</th>
<th>Model I Reference</th>
<th>Model II Reference</th>
<th>Model III Reference</th>
<th>Model IV Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low Adherence (MeD Score, 0–3); n=6632</td>
<td>HR=1.03 (95% CI, 0.84–1.26); (P=0.779)</td>
<td>HR=0.94 (95% CI, 0.77–1.15); (P=0.559)</td>
<td>HR=0.97 (95% CI, 0.80–1.19); (P=0.802)</td>
<td>HR=1.00 (95% CI, 0.82–1.23); (P=0.996)</td>
<td>HR=0.96 (95% CI, 0.78–1.20); (P=0.752)</td>
</tr>
<tr>
<td>Moderate Adherence (MeD Score, 4–5); n=8354</td>
<td>nstrokes=222</td>
<td>HR=0.78 (95% CI, 0.61–1.00); (P=0.047)</td>
<td>HR=0.69 (95% CI, 0.54–0.88); (P=0.003)</td>
<td>HR=0.73 (95% CI, 0.57–0.94); (P=0.013)</td>
<td>HR=0.76 (95% CI, 0.60–0.98); (P=0.034)</td>
</tr>
<tr>
<td>High Adherence (MeD Score, 6–9); n=5211</td>
<td>nstrokes=108</td>
<td>HR=0.69 (95% CI, 0.54–0.88); (P=0.003)</td>
<td>HR=0.73 (95% CI, 0.57–0.94); (P=0.013)</td>
<td>HR=0.76 (95% CI, 0.60–0.98); (P=0.034)</td>
<td>HR=0.78 (95% CI, 0.60–1.01); (P=0.057)</td>
</tr>
</tbody>
</table>

- Model I adjusts for age, race, age-race interaction, region, sex. Model II adjusts for age, race, age-race interaction, region, sex, income, education. Model III adjusts for age, race, age-race interaction, region, sex, income, education, total energy, smoking status, sedentary behavior. Model IV adjusts for age, race, age-race interaction, region, sex, income, education, total energy, smoking status, sedentary behavior, history of heart disease, atrial fibrillation, BMI, waist circumference, DM, HTN, HTN medication use, systolic and diastolic blood pressure.

Tsivgoulis et al., 2015
## Meta-analysis: MeD Adherence and CV Outcomes in RCT

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>log(Risk Ratio)</th>
<th>SE</th>
<th>Weight</th>
<th>IV, Random, 95% CI Year</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MI incidence</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Singh et al, 2002</td>
<td>-0.755</td>
<td>0.2643</td>
<td>28.6%</td>
<td>0.47 [0.28, 0.79] 2002</td>
</tr>
<tr>
<td>Giannuzzi et al, 2008</td>
<td>-0.6539</td>
<td>0.2639</td>
<td>28.7%</td>
<td>0.52 [0.31, 0.87] 2008</td>
</tr>
<tr>
<td>Estruch et al, 2013</td>
<td>-0.2614</td>
<td>0.2003</td>
<td>42.7%</td>
<td>0.77 [0.52, 1.14] 2013</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td></td>
<td></td>
<td>100.0%</td>
<td>0.60 [0.44, 0.82]</td>
</tr>
<tr>
<td><strong>Stroke incidence</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Giannuzzi et al, 2008</td>
<td>-0.1744</td>
<td>0.4047</td>
<td>14.5%</td>
<td>0.84 [0.38, 1.86] 2008</td>
</tr>
<tr>
<td>Estruch et al, 2013</td>
<td>-0.4943</td>
<td>0.1667</td>
<td>85.5%</td>
<td>0.61 [0.44, 0.85] 2013</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td></td>
<td></td>
<td>100.0%</td>
<td>0.64 [0.47, 0.86]</td>
</tr>
<tr>
<td><strong>CVD mortality</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>de Lorgeril et al, 1999</td>
<td>-1.0498</td>
<td>0.4323</td>
<td>18.8%</td>
<td>0.35 [0.15, 0.82] 1999</td>
</tr>
<tr>
<td>Singh et al, 2002</td>
<td>-1.1087</td>
<td>0.4753</td>
<td>16.5%</td>
<td>0.33 [0.13, 0.84] 2002</td>
</tr>
<tr>
<td>Giannuzzi et al, 2008</td>
<td>-0.2877</td>
<td>0.3081</td>
<td>27.8%</td>
<td>0.75 [0.41, 1.37] 2008</td>
</tr>
<tr>
<td>Estruch et al, 2013</td>
<td>-0.1863</td>
<td>0.2193</td>
<td>36.9%</td>
<td>0.83 [0.54, 1.28] 2013</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td></td>
<td></td>
<td>100.0%</td>
<td>0.59 [0.38, 0.93]</td>
</tr>
<tr>
<td><strong>Composite</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>de Lorgeril et al, 1999</td>
<td>-1.273</td>
<td>0.3185</td>
<td>16.0%</td>
<td>0.28 [0.15, 0.52] 1999</td>
</tr>
<tr>
<td>Singh et al, 2002</td>
<td>-0.734</td>
<td>0.1912</td>
<td>25.5%</td>
<td>0.48 [0.33, 0.70] 2002</td>
</tr>
<tr>
<td>Giannuzzi et al, 2008</td>
<td>-0.4005</td>
<td>0.1809</td>
<td>26.5%</td>
<td>0.67 [0.47, 0.96] 2008</td>
</tr>
<tr>
<td>Estruch et al, 2013</td>
<td>-0.3425</td>
<td>0.1211</td>
<td>32.0%</td>
<td>0.71 [0.56, 0.90] 2013</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td></td>
<td></td>
<td>100.0%</td>
<td>0.55 [0.39, 0.76]</td>
</tr>
</tbody>
</table>
Figure 4. Pooled risk ratios of individual Mediterranean diet components and composite CVD outcomes.

<table>
<thead>
<tr>
<th>Med diet Component</th>
<th>Risk Ratio IV, Random, 95% CI</th>
<th>Risk Ratio IV, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol</td>
<td>0.97 [0.88, 1.07]</td>
<td></td>
</tr>
<tr>
<td>Cereals</td>
<td>0.95 [0.90, 1.00]</td>
<td></td>
</tr>
<tr>
<td>Dairy products</td>
<td>1.10 [1.02, 1.19]</td>
<td></td>
</tr>
<tr>
<td>Fish</td>
<td>0.96 [0.91, 1.01]</td>
<td></td>
</tr>
<tr>
<td>Fruit</td>
<td>0.88 [0.81, 0.96]</td>
<td></td>
</tr>
<tr>
<td>Legumes</td>
<td>0.90 [0.83, 0.98]</td>
<td></td>
</tr>
<tr>
<td>Meat</td>
<td>1.02 [0.96, 1.08]</td>
<td></td>
</tr>
<tr>
<td>Olive oil</td>
<td>0.83 [0.77, 0.89]</td>
<td></td>
</tr>
<tr>
<td>Vegetable</td>
<td>0.87 [0.77, 0.98]</td>
<td></td>
</tr>
</tbody>
</table>

Grosso et al., 2015
Implications for MeD & Stroke

- PREDIMED Trial found significant reduction in composite score of MI, stroke and CV mortality
- MeD diet significantly decreased stroke (of the 3 in composite score)
- MeD diet benefit found to influence outcomes in dose dependent manner, the more compliant with diet the greater the benefit
- Meta-analysis show benefit for MI, stroke and CV mortality
- Meta-analysis show major food group contributors:
  - Legumes
  - Fruits, Vegetables
  - Olive Oil
  - +/- complex grains
Emerging Evidence: Gut Microbia and Stroke
Integrative Medicine Paradigm for Gut

- Major immune organ
- Stress (psychological or physiological) causes alterations in gut microbiota and gut barrier
- Once gut barrier is compromised large proteins are passed and activate immune system
- This alteration of gut microbiota then causes systemic effects
- Gut motility dysfunction also causes gut microbiota alteration
Trimethylamine (TMA)-containing nutrients (phosphatidylcholine, choline, and carnitine) are used by gut microbes as a carbon fuel.

TMAO increases platelet (Plt) aggregation in human serum and to immobile collagen tissue under shear force (in vitro).

TMAO increases in vivo thrombosis in mouse carotid.

Wu et al., 2016
Emerging Evidence: Gut Microbia and Platelet Aggregation

- High choline diets and subsequent TMAO levels were associated with specific gut microbia.
- High TMAO levels and platelet aggregation is transferable with FMT.
- Prospective observation study in > 4,000 patients followed in cardiology clinic -> dose response relationship between TMAO blood levels and 3 yr CV event rate (MI, CVA, death, revascularization)

Wu et al., 2016
Emerging Evidence: Gut Dysbiosis & Stroke

- 3 day post MCA ischemic stroke -> decreased gut microbiota diversity
  - Firmicutes, Bacteroidetes, and Actinobacteria
  - Stroke -> significantly reduced gut motility compared to sham

Singh V et al., 2016
Microbiota Transplantation (FMT) from Stroke Mice Worsens Outcome

Singh V et al., 2016
Behavioral & Immunological Outcomes After Either Sham or Stroke FMT

Singh V et al., 2016
Healthy FMT Protective in Stroke
- Healthy FMT vs Vehicle given Day 1 of MCA Stroke

Singh V et al., 2016
Implications for Gut Microbia in Stroke

- High Choline Diet increases gut microbia that favor Plt aggregation, carotid artery stenosis and further alterations in gut microbia favoring more 'harmful' populations.

- Stroke alters gut microbia and motility in animal model that is associated with larger stroke volume and poorer motor outcomes.

- Poorer stroke outcome can be induced with FMT.

- FMT can be neuroprotective if given within first day of stroke reducing stroke volume and increasing gut microbia variability.
Controversies: Vit D and CV Risk
Vit D Implications on CV Benefit

- **Background**
  - CV events higher in countries furthest from equator and of higher altitude
  - More CV events reported in winter months

- **Physiological Data**
  - Vit D receptor (VDR) -/- mice have increased renin receptor, All, & aldosterone (RAS activation).
  - RAS activation normalized with 1-25(OH)D
  - VDR -/- mice -> ventricular hypertrophy & HTN, which is reversed with Vit D supplementation
  - Enzymatic, nutritional or VDR deficiencies -> increased atherosclerosis, thrombosis, and peripheral vascular resistance in rodents
  - Implicated in murine vascular tone modulation via Ca\(^+\) and COX-1
  - Promotes carotid artery repair (reendothelialization) in diabetic mice
  - Anticoagulant properties by reducing inhibition of plasminogen activator
Vit D: Observational Studies

- Low 25(OH)D correlated with:
  - Increased Hypertension (Women’s Health Study, Health Professional’s Followup & Nurses’ Health Study)
  - Peripheral Vascular Disease (National Health and Nutritional Examination Survey)
  - Myocardial Infarction (Health Professional’s Follow-up)
  - Cardiovascular Mortality (prospective cohort study of patient going for angiography)
  - Fatal Stroke (Ludwigshafen Risk and Cardiovascular Health Study)
  - Cardiovascular Disease (Framingham Cohort; only in hypertensive patients)
  - Fatal Cardiovascular Events & Early Death (Copenhagen City Heart Study)
  - Ischemic Stroke (Umbrella meta-analysis)
Vit D: Supplementation RCT

- 2800 IU x 8 weeks -> no effect:
  - Systolic or diastolic BP, HDL, Renin or Aldosterone

- 800 IU x 24-62 months 70 yo -> no effect
  - Stroke Mortality, CV Mortality, All Cause Mortality

- 400 & 1000 IU -> no effect
  - CV events or Stroke

- Meta-Analysis of RCT -> no effect
  - Stroke, MI, mortality,
  - Surrogate outcomes - lipid fractions, glucose, systolic or diastolic BP

- VITAL Trial
  - RTC of 25,875 US sample to receive 2000 IU D3, OM3FA, both or placebo
  - Treatment duration 5 yrs
  - Outcome = cancer and CV Events (MI, Stroke, CV death)
- Vit D significantly inversely related to infarct volume (A) and infarct type (lacunar stroke) (C)
- Risk for a 90 day poor modified Rankin Scale score (3-6) was doubled with every 10 ng/mL decrease in 25(OH)D level (table not shown)

Turetsky et al., 2015
Implications for Vit D in Stroke

- While physiological and observational studies support a role for Vit D in stroke, the RCT with Vit D supplementation have not supported a role for Vit D supplementation and stroke prevention.

- VITAL Trial data with larger sample size and adequate Vit D supplementation, will start reporting findings in 2017.

- Early data suggest Vit D may be related to stroke volume and 90 day clinical outcomes.
Must Do’s: Mindfulness
Must Do’s: Mindfulness

- Mindfulness is the nonjudgmental attention to the present moment

- Significantly reduced depression, anxiety, headache, pain in medical and non-medical patients

Kabat-Zinn, 1990
Mindfulness & Stroke

- Improvement in depression and anxiety depending on study design
- No significant improvement in BP for stroke
- Clear improvement in Quality of Life scales

Abbott et al., 2014: Lawrence et al., 2013
### Table 9: Perceived general health and quality of life

<table>
<thead>
<tr>
<th>Study</th>
<th>Measure</th>
<th>Pretest mean (SD)</th>
<th>Posttest mean (SD)</th>
<th>Follow-up mean (SD)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moustgaard et al. (46)</td>
<td>SF-36 PCS</td>
<td>39.19 (6.21)</td>
<td>46.78 (7.73)</td>
<td>45.73 (8.74)</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td>SF-36 MCS</td>
<td>48.55 (10.14)</td>
<td>56.10 (6.40)</td>
<td>53.95 (10.60)</td>
<td>0.002</td>
</tr>
<tr>
<td></td>
<td>SS-QoL (total)</td>
<td>285.95 (37.05)</td>
<td>321.81 (38.31)</td>
<td>326.19 (38.94)</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td>SS-QoL <strong>Energy</strong></td>
<td>12.24 (4.13)</td>
<td>15.24 (3.83)</td>
<td>15.86 (3.93)</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td>SS-QoL Family role</td>
<td>27.57 (8.75)</td>
<td>31.0 (7.74)</td>
<td>31.48 (7.35)</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td>SS-QoL Mobility</td>
<td>45.38 (12.10)</td>
<td>49.71 (10.28)</td>
<td>50.48 (10.13)</td>
<td>0.004</td>
</tr>
<tr>
<td></td>
<td>SS-QoL Mood</td>
<td>29.91 (6.95)</td>
<td>33.62 (5.60)</td>
<td>33.57 (5.15)</td>
<td>0.013</td>
</tr>
<tr>
<td></td>
<td>SS-QoL Personality</td>
<td>11.48 (5.14)</td>
<td>16.38 (3.57)</td>
<td>16.81 (3.40)</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td>SS-QoL Self-care</td>
<td>34.67 (4.31)</td>
<td>36.57 (3.76)</td>
<td>36.57 (3.92)</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td>SS-QoL Social roles</td>
<td>19.76 (7.85)</td>
<td>25.29 (6.07)</td>
<td>26.10 (5.82)</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td>SS-QoL Thinking</td>
<td>11.29 (3.12)</td>
<td>14.43 (2.25)</td>
<td>14.81 (2.11)</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td>SS-QoL <strong>Upper extremity</strong></td>
<td>36.33 (8.57)</td>
<td>38.57 (7.93)</td>
<td>38.86 (7.95)</td>
<td>0.007</td>
</tr>
<tr>
<td></td>
<td>SS-QoL Vision</td>
<td>16.76 (4.56)</td>
<td>17.71 (3.81)</td>
<td>17.95 (3.32)</td>
<td>0.017</td>
</tr>
<tr>
<td></td>
<td>SS-QoL Work</td>
<td>8.91 (3.46)</td>
<td>10.76 (3.25)</td>
<td>10.95 (3.19)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

MCS, mental component score; PCS, physical component score; SF-36, 36-Item Short-Form General Health Survey; SS-QoL, Stroke Specific Quality of Life Scale.
Implications for Mindfulness & Stroke

- In stroke as with other medical populations, mindfulness decreases anxiety & depression
- QOL significantly improved in stroke patients who participated in mindfulness practice including:
  - Energy
  - Self Care
  - Upper extremity use
Resources for Integrative Medicine

- National Center for Integrative and Complementary Health
  - https://nccih.nih.gov/research/results/spotlight

- Natural Medicines
  - https://naturalmedicines.therapeuticresearch.com

- Consumer labs
  - https://www.consumerlab.com
Summary

- MeD has observational and RCT evidence for risk reduction of stroke and mortality.
- Gut microbiota increase platelet aggregation in serum and endothelial surface, and increases atherosclerosis in animal models.
- Animal studies show gut microbiota and motility significantly altered in stroke. This altered microbiota increases stroke severity in FMT. Healthy FMT can be protective if given early in stroke.
- While RTC outcomes thus far on role of Vit D in stroke is still forthcoming, there is implication for lower Vit D and poorer stroke outcome.
- Mindfulness practice may improve overall QOL but especially consider in patients with low energy, upper extremity weakness.
Thank You
References

- Carvalho LS & Sposito AC. Vitamin D for the Prevention of Cardiovascular Disease: Are We Ready for that? Athersclerosis (2015) 241:729-740
References Cont:


- **Theodoratou E et al.** Vitamin D and Multiple Health Outcomes: Umbrella Review of Systematic Reviews and Meta-analyses of Observational Studies and Randomised Trials. *BMJ* 2014;348:g2035doi:10.1136/bmj.g2035


